our story and vision
Context Therapeutics is dedicated to creating new medicines to treat hormone responsive (HR+) cancers.
We seek to become a global company that will discover, develop and market groundbreaking cancer treatments to patients around the world, eliminating the fear that comes with a cancer diagnosis.
Context’s lead program is Apristor®, an investigational Phase 2 drug that is being developed for progesterone receptor positive (PR+) cancers.
advancing medicines for hormone driven cancers
Hormone receptor positive (HR+) cancers, including breast, uterine (endometrial), and ovarian cancers are poorly addressed and result in over 75,000 deaths per year in the United States.
HR+ cancers are driven by the binding of hormones (e.g., progesterone or estrogen) to their partner receptors (referred to as “nuclear receptors”).
HR+ cancers are poorly responsive to immune oncology (“I-O”) therapeutics due to the inherent “cold” nature of HR+ tumors, lack of cell surface targets, and limited production of neoantigens.
by antagonizing progesterone receptor driven signaling
Nuclear receptors are a class of transcriptional regulatory proteins. We are focused on a subset of these receptors that are activated by hormones, in particular the progesterone receptor which is activated by progesterone.
Progesterone receptor is enriched in breast, ovarian, and endometrial cancers.
Unlike existing PR-targeting drugs, only Apristor is selective for PR and has shown robust monotherapy clinical activity.
capturing the Potential of Progesterone Receptor Antagonism
Nuclear receptors, including the progesterone receptor (PR), are attractive targets for hormone-driven cancers. However, developing therapeutics that selectivity block specific nuclear receptors while retaining sufficient oral bioavailability has limited the potential of this therapeutic class.
Context Therapeutics is a leader in nuclear receptor drug development, with a particular focus on developing progesterone receptor antagonists.
Progesterone receptor (PR) antagonists have potential in:
Low Grade Serous Ovarian Cancer
A rare, slow-growing cancer that is generally resistant to cytotoxic chemotherapy. 80-90% of patients express progesterone receptor.
It is estimated that there are approximately 100,000 patients with recurrent disease worldwide.
Granulosa Cell Tumor of Ovary
A rare, slow-growing cancer that is generally resistant to cytotoxic chemotherapy. Hormonally active tumors that synthesize high levels of progesterone.
It is estimated that there are approximately 50,000 patients with recurrent disease worldwide.
~70% of breast cancers are driven by aberrant hormone signaling. In the recurrent setting, progesterone receptor has emerged as a prominent resistance mechanism.
It is estimated that there are over 750,000 patients with recurrent disease worldwide.
The most common gynecological malignancy. Up to 90% of patients express the progesterone receptor.
It is estimated that there are over 200,000 patients with recurrent disease worldwide.